Yahoo Poland Wyszukiwanie w Internecie

Search results

1. ir.alzamend.com › news-events › press-releasesAlzamend Neuro Announces Full Data Set from Phase IIA Multiple...

   ir.alzamend.com › news-events › press-releases

   • Zapisane w pamięci cache

   2 dni temu · About Alzamend Neuro. Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BPD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ...

2. pl.investing.com › news › company-newsAlzamend Neuro ponownie spełnia wymogi Nasdaq dotyczące kapitału...

   pl.investing.com › news › company-news

   • Zapisane w pamięci cache

   4 dni temu · ATLANTA - Alzamend Neuro, Inc. (NASDAQ:ALZN), firma biofarmaceutyczna w fazie klinicznej, ogłosiła, że ponownie spełnia wymogi Nasdaq dotyczące kapitału własnego akcjonariuszy. Spółka, która pracuje nad terapiami na chorobę Alzheimera i inne zaburzenia psychiczne, otrzymała 14.10.2024 r. oficjalne powiadomienie od Nasdaq Stock ...

3. www.biospace.com › press-releases › alzamend-neuro-regains-compliance-with-nasdaqAlzamend Neuro Regains Compliance with Nasdaq Listing Standards

   www.biospace.com › press-releases › alzamend-neuro-regains-compliance-with-nasdaq

   • Zapisane w pamięci cache

   3 dni temu · About Alzamend Neuro. Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. ... 3 Biotechs Seek Over $700M in Renewed IPO Rush. September 13, 2024 · 2 min read · Annalee ...

4. www.marketscreener.com › quote › stockAlzamend Neuro : Regains Compliance with Nasdaq Listing Standards...

   www.marketscreener.com › quote › stock

   • Zapisane w pamięci cache

   4 dni temu · Alzamend Neuro Regains Compliance with Nasdaq Listing Standards. ATLANTA, GA, October 15, 2024 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today ...

5. stockanalysis.com › stocks › alznAlzamend Neuro, Inc. (ALZN) - Stock Analysis

   stockanalysis.com › stocks › alzn

   • Zapisane w pamięci cache

   4 dni temu · Get a real-time Alzamend Neuro, Inc. (ALZN) stock price quote with breaking news, financials, statistics, charts and more.

6. ir.alzamend.comAlzamend Neuro, Inc. (ALZN)

   ir.alzamend.com

   • Zapisane w pamięci cache

   10 paź 2024 · Alzamend strives to provide hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders, through advanced research and development.

7. alzamend.com › featured › alzamend-neuro-announces-pricing-of-initial-public-offeringAlzamend Neuro Announces Pricing of Initial Public Offering

   alzamend.com › featured › alzamend-neuro-announces-pricing-of-initial-public-offering

   • Zapisane w pamięci cache

   3 sty 2017 · The gross proceeds from the offering to Alzamend, before deducting underwriting discounts and commissions and other offering expenses payable by Alzamend, are expected to be $12.5 million. In addition, the underwriters have been granted a 45-day option to purchase up to an additional 375,000 shares of common stock, at the initial public ...